The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.
about
Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.Identification of immunohistochemical markers for distinguishing lung adenocarcinoma from squamous cell carcinomaExpression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitationsThe impact of immunohistochemistry on the classification of lung tumors.The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas.The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.Biomarkers in the accurate subclassification of non-small-cell lung carcinoma for targeted therapy: issues and prospects.Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.Cytomorphology of sebaceous carcinoma with analysis of p40 antibody expression.
P2860
Q35561933-E7577894-8642-4A4C-8CEC-D2036649043AQ36031798-0D130B81-6BED-42A2-AD99-C4B6F7FB0FF8Q36152375-3E5EB29A-BF5C-427D-8B9B-D23C45CA0019Q38822314-2BC0D09D-06C1-4903-8328-F69DD14416D0Q40477156-792214A0-51D0-4A12-92CE-BB2887BE144FQ41732728-7A3BD3CD-E8C2-4BBD-9AAC-DA1BEB2AD28CQ47136556-B5D7A0F7-9349-49E4-A2FB-5F4DBB57254DQ47813304-1BC91342-4D23-4715-B246-EEC089DBD8E6Q48088758-7B776A77-4C03-4A6E-975B-EA523AB7E8CEQ50941101-35E1FDAA-9C0D-414E-B25D-2DC1F4ED4E26Q51643436-E08DB542-0E3A-4AF2-9B08-DE25B7A0A9E6Q53631524-634CFDA8-F670-4F32-8578-331965C655B4
P2860
The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The utility of a novel triple ...... of non-small cell lung cancer.
@ast
The utility of a novel triple ...... of non-small cell lung cancer.
@en
The utility of a novel triple ...... of non-small cell lung cancer.
@nl
type
label
The utility of a novel triple ...... of non-small cell lung cancer.
@ast
The utility of a novel triple ...... of non-small cell lung cancer.
@en
The utility of a novel triple ...... of non-small cell lung cancer.
@nl
prefLabel
The utility of a novel triple ...... of non-small cell lung cancer.
@ast
The utility of a novel triple ...... of non-small cell lung cancer.
@en
The utility of a novel triple ...... of non-small cell lung cancer.
@nl
P2093
P2860
P1433
P1476
The utility of a novel triple ...... of non-small cell lung cancer.
@en
P2093
Edward Gabrielson
Frederic Askin
Lynne Sakowski
Ming-Hui Ao
Peter B Illei
Qing Kay Li
P2860
P304
P356
10.1016/J.HUMPATH.2014.01.005
P407
P577
2014-01-25T00:00:00Z